Multiomic Characterization of and Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes.
[PURPOSE] Regulator of chromosome condensation 1 () and have been shown to play important roles in the regulation of cell cycle, DNA damage response, and nucleocytoplasmic transport.
- 표본수 (n) 876
APA
Nagasaka M, Warnecke B, et al. (2025). Multiomic Characterization of and Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes.. JCO oncology advances, 2(1), 00022. https://doi.org/10.1200/OA-24-00033
MLA
Nagasaka M, et al.. "Multiomic Characterization of and Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes.." JCO oncology advances, vol. 2, no. 1, 2025, pp. 00022.
PMID
40330141
Abstract
[PURPOSE] Regulator of chromosome condensation 1 () and have been shown to play important roles in the regulation of cell cycle, DNA damage response, and nucleocytoplasmic transport.
[MATERIALS AND METHODS] DNA (592-gene or whole exome) and RNA (whole transcriptome) sequencing was performed at Caris Life Sciences (Phoenix, AZ). Samples were stratified by expression quartile thresholds (Q1: low, Q4: high) for small cell lung cancer (SCLC; n = 876), non-small cell lung cancer (NSCLC; n = 21,603), gastric cancer (GC; n = 1,908), pancreatic cancer (PC; n = 5,071), and colorectal cancer (CRC; n = 14,892). Statistical significance was determined using chi-square and Wilcoxon rank-sum tests and adjusted for multiple comparisons (* < .05). Corresponding analyses were run for .
[RESULTS] Median mRNA expression was highest in SCLC (14.3 transcript per million [TPM]), followed by GC (9.9), NSCLC (9.9), CRC (9.8), and PC (6.9). Similar to , the median expressions were highest in SCLC (36.2 TPM). Tumor mutational burden-high rates were positively associated with increasing expression quartiles (Q1-4) in NSCLC (31%-41%), GC (7%-22%), and CRC (5%-17%) and with increasing expression in NSCLC and CRC only. Higher expression with and was associated with worse overall survival in NSCLC (hazard ratio [HR] for and were 1.3 and 1.3, respectively), PC (HR for and were 1.5 and 1.12, respectively), and CRC (HR for and were 1.3 and 1.03, respectively).
[CONCLUSION] and expression is a negative prognostic marker in NSCLC, PC, and CRC. Further studies to investigate and function at the molecular level may provide opportunities for novel targeted drug development.
[MATERIALS AND METHODS] DNA (592-gene or whole exome) and RNA (whole transcriptome) sequencing was performed at Caris Life Sciences (Phoenix, AZ). Samples were stratified by expression quartile thresholds (Q1: low, Q4: high) for small cell lung cancer (SCLC; n = 876), non-small cell lung cancer (NSCLC; n = 21,603), gastric cancer (GC; n = 1,908), pancreatic cancer (PC; n = 5,071), and colorectal cancer (CRC; n = 14,892). Statistical significance was determined using chi-square and Wilcoxon rank-sum tests and adjusted for multiple comparisons (* < .05). Corresponding analyses were run for .
[RESULTS] Median mRNA expression was highest in SCLC (14.3 transcript per million [TPM]), followed by GC (9.9), NSCLC (9.9), CRC (9.8), and PC (6.9). Similar to , the median expressions were highest in SCLC (36.2 TPM). Tumor mutational burden-high rates were positively associated with increasing expression quartiles (Q1-4) in NSCLC (31%-41%), GC (7%-22%), and CRC (5%-17%) and with increasing expression in NSCLC and CRC only. Higher expression with and was associated with worse overall survival in NSCLC (hazard ratio [HR] for and were 1.3 and 1.3, respectively), PC (HR for and were 1.5 and 1.12, respectively), and CRC (HR for and were 1.3 and 1.03, respectively).
[CONCLUSION] and expression is a negative prognostic marker in NSCLC, PC, and CRC. Further studies to investigate and function at the molecular level may provide opportunities for novel targeted drug development.